Market Overview

BioCryst Announces Additional $2,5M NIAID Funding to Advance Development of BCX4430 to Treat Marburg Virus Disease


Pharmaceuticals (NASDAQ: BCRX) today announced that the National
Institute of Allergy and Infectious Diseases (NIAID) has exercised
an option to conduct the investigational new drug (IND) enabling program
and to submit an IND. This option represents an additional $2.5 million
to BioCryst in order to advance the development of BCX4430
as a treatment for Marburg virus disease. NIAID, part of the National
Institutes of Health, granted an initial award of $5.0 million to
BioCryst in September 2013. The total funding could be up to $22.0
million over five years and advance the program through Phase 1 trials,
if all contract options are exercised.

“With these additional funds, BioCryst will rapidly initiate

See full press release

Posted-In: News Guidance Financing Offerings Contracts Management Global


Related Articles (BCRX)

View Comments and Join the Discussion!

Barron's Recap: Home Prices Ready To Rise

Gas Natural Names MaloneBailey as Independent Auditing Firm